A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

Feng Jin1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People’s Republic of China;2 Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of China

Hui Zhu1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People’s Republic of China;2 Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of China

Fang Shi1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People’s Republic of China;2 Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of China

Li Kong1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People’s Republic of China;2 Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of China

Jinming Yu1 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, University of Jinan, Jinan, Shandong Province, People’s Republic of China;2 Shandong Academy of Medical Sciences, University of Jinan, Jinan, Shandong Province, People’s Republic of ChinaCorrespondence[email protected]

Pages 167-173 | Published online: 19 Feb 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

SocinskiMAEvansTGettingerSTreatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesChest20131435 suppl341s368s
Web of Science ®Google Scholar
HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2010Bethesda, MDNational Cancer Institute2013
Google Scholar
CarnioSNovelloSMeleTLevraMGScagliottiGVExtending survival of stage IV non-small cell lung cancerSemin Oncol2014411699224565582
PubMed Web of Science ®Google Scholar
JohnVMashruSLichtmanSMPharmacological factors influencing anticancer drug selection in the elderlyDrugs Aging2003201073775912875610
PubMed Web of Science ®Google Scholar
SunYWuYLZhouCCSecond-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label studyLung Cancer201379214315023182660
PubMed Web of Science ®Google Scholar
GarassinoMCMartelliOBrogginiMTAILOR TrialistsErlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialLancet Oncol2013141098198823883922
PubMed Web of Science ®Google Scholar
PalumboRSottotettiFTrifiròGNanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in her 2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of lifeDrug Des Devel Ther2015921892199
PubMed Web of Science ®Google Scholar
RizviNARielyGJAzzoliCGPhase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancerJ Clin Oncol200826463964318235124
PubMed Web of Science ®Google Scholar
SocinskiMALangerCJOkamotoISafety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancerAnn Oncol201324231432123123509
PubMed Web of Science ®Google Scholar
AaproMTjulandinSBharPGradisharWWeekly nab-paclitaxel is safe and effective in 65 years old patients with metastatic breast cancer: a post-hoc analysisBreast201120546847421843943
PubMed Web of Science ®Google Scholar
GreenMRManikhasGMOrlovSAbraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancerAnn Oncol20061781263126816740598
PubMed Web of Science ®Google Scholar
ZhengQYaoYNanKWeekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 casesJ Biomed Res201226315916423554745
PubMedGoogle Scholar
TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
PubMed Web of Science ®Google Scholar
SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol201230172055206222547591
PubMed Web of Science ®Google Scholar
GuptaNHatoumHDyGKFirst line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxelInt J Nanomedicine2014920922124399877
PubMed Web of Science ®Google Scholar
YardleyDAnab-Paclitaxel mechanisms of action and deliveryJ Control Release2013170336537223770008
PubMed Web of Science ®Google Scholar
JoergerMMetabolism of the taxanes including nab-paclitaxelExpert Opin Drug Metab Toxicol201511569170225394848
PubMed Web of Science ®Google Scholar
HuangTCCampbellTCComparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysisCancer Treat Rev201238661361722155063
PubMed Web of Science ®Google Scholar
GotoYSekineIYamadaKInfluence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patientsJ Thorac Oncol20083441241618379361
PubMed Web of Science ®Google Scholar
WiedenmannNValdecanasDHunterN130-nm Albumin bound paclitaxel enhances tumor radiocurability and therapeutic gainClin Cancer Res20071361868187417363543
PubMed Web of Science ®Google Scholar
LangerCJHirshVKoARenschlerMFSocinskiMAWeekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairmentClin Lung Cancer201516211212025572008
PubMed Web of Science ®Google Scholar
SimonGRnab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive updateClin Lung Cancer201415639139725246384
PubMed Web of Science ®Google Scholar
GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
PubMed Web of Science ®Google Scholar
BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancerN Engl J Med2015373212313526028407
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date